Loading [MathJax]/jax/output/SVG/jax.js
Overview Topical Sections

SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses

  • In recent weeks, the rate of SARS-CoV-2 infections has been progressively increasing all over the globe, even in countries where vaccination programs have been strongly implemented. In these regions in 2021, a reduction in the number of hospitalizations and deaths compared to 2020 was observed. This decrease is certainly associated with the introduction of vaccination measures. The process of the development of effective vaccines represents an important challenge. Overall, the breakthrough infections occurring in vaccinated subjects are in most cases less severe than those observed in unvaccinated individuals. This review examines the factors affecting the immunogenicity of vaccines against SARS-CoV-2 and the possible role of nutrients in modulating the response of distinct immune cells to the vaccination.

    Citation: Sirio Fiorino, Andrea Carusi, Wandong Hong, Paolo Cernuschi, Claudio Giuseppe Gallo, Emanuele Ferrara, Thais Maloberti, Michela Visani, Federico Lari, Dario de Biase, Maddalena Zippi. SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses[J]. AIMS Microbiology, 2022, 8(4): 422-453. doi: 10.3934/microbiol.2022029

    Related Papers:

    [1] Martin Gugat, Rüdiger Schultz, Michael Schuster . Convexity and starshapedness of feasible sets in stationary flow networks. Networks and Heterogeneous Media, 2020, 15(2): 171-195. doi: 10.3934/nhm.2020008
    [2] Martin Gugat, Falk M. Hante, Markus Hirsch-Dick, Günter Leugering . Stationary states in gas networks. Networks and Heterogeneous Media, 2015, 10(2): 295-320. doi: 10.3934/nhm.2015.10.295
    [3] Mapundi K. Banda, Michael Herty, Axel Klar . Gas flow in pipeline networks. Networks and Heterogeneous Media, 2006, 1(1): 41-56. doi: 10.3934/nhm.2006.1.41
    [4] Michael Herty . Modeling, simulation and optimization of gas networks with compressors. Networks and Heterogeneous Media, 2007, 2(1): 81-97. doi: 10.3934/nhm.2007.2.81
    [5] Markus Dick, Martin Gugat, Günter Leugering . Classical solutions and feedback stabilization for the gas flow in a sequence of pipes. Networks and Heterogeneous Media, 2010, 5(4): 691-709. doi: 10.3934/nhm.2010.5.691
    [6] Mapundi K. Banda, Michael Herty, Axel Klar . Coupling conditions for gas networks governed by the isothermal Euler equations. Networks and Heterogeneous Media, 2006, 1(2): 295-314. doi: 10.3934/nhm.2006.1.295
    [7] Jens Lang, Pascal Mindt . Entropy-preserving coupling conditions for one-dimensional Euler systems at junctions. Networks and Heterogeneous Media, 2018, 13(1): 177-190. doi: 10.3934/nhm.2018008
    [8] Gen Qi Xu, Siu Pang Yung . Stability and Riesz basis property of a star-shaped network of Euler-Bernoulli beams with joint damping. Networks and Heterogeneous Media, 2008, 3(4): 723-747. doi: 10.3934/nhm.2008.3.723
    [9] Markus Musch, Ulrik Skre Fjordholm, Nils Henrik Risebro . Well-posedness theory for nonlinear scalar conservation laws on networks. Networks and Heterogeneous Media, 2022, 17(1): 101-128. doi: 10.3934/nhm.2021025
    [10] Gunhild A. Reigstad . Numerical network models and entropy principles for isothermal junction flow. Networks and Heterogeneous Media, 2014, 9(1): 65-95. doi: 10.3934/nhm.2014.9.65
  • In recent weeks, the rate of SARS-CoV-2 infections has been progressively increasing all over the globe, even in countries where vaccination programs have been strongly implemented. In these regions in 2021, a reduction in the number of hospitalizations and deaths compared to 2020 was observed. This decrease is certainly associated with the introduction of vaccination measures. The process of the development of effective vaccines represents an important challenge. Overall, the breakthrough infections occurring in vaccinated subjects are in most cases less severe than those observed in unvaccinated individuals. This review examines the factors affecting the immunogenicity of vaccines against SARS-CoV-2 and the possible role of nutrients in modulating the response of distinct immune cells to the vaccination.



    In this paper we deal with the following fractional Choquard equation

    (Δ)su+μu=(IαF(u))f(u)inRN (1.1)

    where N2, μ>0, s(0,1), α(0,N), (Δ)s and Iα denote respectively the fractional Laplacian and the Riesz potential defined by

    (Δ)su(x):=CN,sRNu(x)u(y)|xy|N+2sdy,Iα(x):=AN,α1|x|Nα,

    where CN,s:=4sΓ(N+2s2)πN/2|Γ(s)| and AN,α:=Γ(Nα2)2απN/2Γ(α2) are two suitable positive constants and the integral is in the principal value sense. Finally F:RR, F=f is a nonlinearity satisfying general assumptions specified below.

    When dealing with double nonlocalities, important applications arise in the study of exotic stars: minimization properties related to (1.1) play indeed a fundamental role in the mathematical description of the gravitational collapse of boson stars [31,53] and white dwarf stars [37]. In fact, the study of the ground states to (1.1) gives information on the size of the critical initial conditions for the solutions of the corresponding pseudo-relativistic equation [48]. Moreover, when s=12, N=3, α=2 and F(t)=1r|t|r, we obtain

    Δu+μu=(12πr|x||u|r)|u|r2uinR3

    related to the well-known massless boson stars equation [29,39,50], where the pseudorelativistic operator Δ+m collapses to the square root of the Laplacian. Other applications can be found in relativistic physics and in quantum chemistry [1,22,38] and in the study of graphene [56], where the nonlocal nonlinearity describes the short time interactions between particles.

    In the limiting local case s=1, when N=3, α=2 and F(t)=12|t|2, the equation has been introduced in 1954 by Pekar in [63] to describe the quantum theory of a polaron at rest. Successively, in 1976 it was arisen in the work [51] suggested by Choquard on the modeling of an electron trapped in its own hole, in a certain approximation to Hartree-Fock theory of one-component plasma (see also [32,33,69]). In 1996 the same equation was derived by Penrose in his discussion on the self-gravitational collapse of a quantum mechanical wave-function [59,64,65,66] (see also [70,71]) and in that context it is referred as Schrödinger-Newton system. Variational methods were also employed to derive existence and qualitative results of standing wave solutions for more generic values of α(0,N) and of power type nonlinearities F(t)=1r|t|r [60] (see also [14,20,49,58,61,62]). The case of general functions F, almost optimal in the sense of Berestycki-Lions [5], has been treated in [19,61].

    The fractional power of the Laplacian appearing in (1.1), when s(0,1), has been introduced instead by Laskin [47] as an extension of the classical local Laplacian in the study of nonlinear Schrödinger equations, replacing the path integral over Brownian motions with Lévy flights. This operator arises naturally in many contexts and concrete applications in various fields, such as optimization, finance, crystal dislocations, charge transport in biopolymers, flame propagation, minimal surfaces, water waves, geo-hydrology, anomalous diffusion, neural systems, phase transition and Bose-Einstein condensation (see [6,25,31,45,46,55] and references therein). Equations involving the fractional Laplacian together with local nonlinearities have been largely investigated, and some fundamental contributions can be found in [9,10,30]. In particular, existence and qualitative properties of the solutions for general classes of fractional NLS equations with local sources have been studied in [7,11,28,41,42].

    Mathematically, doubly nonlocal equations have been treated in [23,24] in the case of pure power nonlinearities (see also [13] for some orbital stability results and [12] for a Strichartz estimates approach), obtaining existence and qualitative properties of the solutions. Other results can be found in [4,57,67] for superlinear nonlinearities, in [36] for L2-supercritical Cauchy problems, in [35] for bounded domains and in [72] for concentration phenomena with strictly noncritical and monotone sources.

    In the present paper we address the study of (1.1) when f satisfies the following set of assumptions of Berestycki-Lions type [5]:

    (f1) fC(R,R);

    (f2) we have

    i)lim supt0|tf(t)||t|N+αN<+,ii)lim sup|t|+|tf(t)||t|N+αN2s<+;

    (f3) F(t)=t0f(τ)dτ satisfies

    i)limt0F(t)|t|N+αN=0,ii)lim|t|+F(t)|t|N+αN2s=0;

    (f4) there exists t0R, t00 such that F(t0)0.

    We observe that (f3) implies that we are in a noncritical setting: indeed the exponents N+αN and N+αN2s have been addressed in [60] as critical for Choquard-type equations when s=1, and then generalized to s(0,1) in [23]; we will assume the noncriticality in order to obtain the existence of a solution, while most of the qualitative results will be given in a possibly critical setting. This kind of general nonlinearities include some particular cases such as pure powers f(t)tr, cooperating powers f(t)tr+th, competing powers f(t)trth and saturable functions f(t)t31+t2 (which arise, for instance, in nonlinear optics [27]).

    We deal first with existence of a ground state for (1.1), obtaining the following result.

    Theorem 1.1. Assume (f1)–(f4). Then there exists a radially symmetric weak solution u of (3.1), which satisfies the Pohozaev identity:

    N2s2RN|(Δ)s/2u|2dx+N2μRNu2dx=N+α2RN(IαF(u))F(u)dx. (1.2)

    This solution is of Mountain Pass type and minimizes the energy among all the solutions satisfying (1.2).

    We refer to Section 3 for the precise meaning of weak solution, of Mountain Pass type and energy, according to a variational formulation of the problem.

    We point out some difficulties which arise in this framework. Indeed, the presence of the fractional power of the Laplacian does not allow to use the fact that every solution satisfies the Pohozaev identity to conclude that a Mountain Pass solution is actually a (Pohozaev) ground state, as in [44] (see Remark 3.5). On the other hand, the presence of the Choquard term, which scales differently from the L2-norm term, does not allow to implement the classical minimization argument by [5,21]. Finally, the nonhomogeneity of the nonlinearity f obstructs the minimization approach of [23,61]. Thus, we need a new approach to get existence of solutions, in the spirit of [16,17,18].

    Under (f1)–(f4) it is moreover possible to state the existence of a constant sign solution (see Proposition 3.6). This motivates the investigation of qualitative properties for general positive solutions; in this case we consider weaker or stronger assumptions in substitution to (f1)–(f3), depending on the result. In particular, we observe that (f1)–(f2) alone imply

    |tf(t)|C(|t|N+αN+|t|N+αN2s),

    and

    |F(t)|C(|t|N+αN+|t|N+αN2s),

    where we notice that the last inequality is weaker than (f3); some of the qualitative results are still valid when F has this possible critical growth. Consider finally the following stronger assumption in the origin:

    (f5) lim supt0|tf(t)||t|2<+,

    and observe that

    (f5)(f2,i)and(f3,i).

    The main qualitative results that we obtain are the following ones.

    Theorem 1.2. Assume (f1)–(f2). Let uHs(RN) be a weak positive solution of (1.1).Then uL1(RN)L(RN). The same conclusion holds for generally signed solutions by assuming also (f5).

    The condition in zero of the function f assumed in (f5) leads also to the following polynomial decay of the solutions.

    Theorem 1.3. Assume (f1)– (f2) and (f5). Let uHs(RN) be a positive weak solution of (1.1). Then there exists C,C>0 such that

    C1+|x|N+2su(x)C1+|x|N+2s,forxRN.

    The previous results generalize some of the ones in [23] to the case of general, not homogeneous, nonlinearities; in particular, we do not even assume f to satisfy Ambrosetti-Rabinowitz type conditions nor monotonicity conditions. We observe in addition that the information uL1(RN)L2(RN) is new even in the power-type setting: indeed in [23] the authors assume the nonlinearity to be not lower critical, while here we include the possibility of criticality. Moreover, we improve the results in [57,67] since we do not assume f to be superlinear, and we have no restriction on the parameter α. Finally, we extend some of the results in [61] to the fractional framework, and some of the results in [7] to Choquard nonlinearities.

    The paper is organized as follows. We start with some notations and recalls in Section 2. In Section 3 we obtain the existence of a ground state in a noncritical setting, and in addition the existence of a positive solution. Section 4 is dedicated to the study of the boundedness of positive solutions, while in Section 5 we investigate the asymptotic decay. Finally in the Appendix A we obtain the boundedness of general signed solutions under some more restrictive assumption.

    Let N2 and s(0,1). Recalled the definition of the fractional Laplacian [25]

    (Δ)su(x)=CN,sRNu(x)u(y)|xy|N+2sdy

    for every s(0,1), we set the fractional Sobolev space as

    Hs(RN)={uL2(RN)(Δ)s/2uL2(RN)}

    endowed with

    u2Hs=u22+(Δ)s/2u22.

    In particular, we consider the subspace of radially symmetric functions Hsr(RN), and recall the continuous embedding [[25], Theorem 3.5]

    Hs(RN)Lp(RN)

    for every p[2,2s], 2s=2NN2s critical Sobolev exponent, and the compact embedding [54]

    Hsr(RN)↪↪Lp(RN)

    for every p(2,2s). In addition we have the following embedding of the homogeneous space [[25], Theorem 6.5] for some S>0

    u2sS1/2(Δ)su2. (2.1)

    Moreover the following relation with the Gagliardo seminorm holds [[25], Proposition 3.6], for some C(N,s)>0

    (Δ)s/2u22=C(N,S)R2N|u(x)u(y)|2|xy|N+2sdxdy. (2.2)

    Thanks to this last formulation, we obtain that if uHs(RN) and h:RR is a Lipschitz function with h(0)=0, then h(u)Hs(RN). Indeed

    h(u)22=RN|h(u)h(0)|2dxRNh2|u0|2dx=h2u22

    and

    (Δ)s/2h(u)22C(N,S)R2Nh2|u(x)u(y)|2|xy|N+2sdxdy=h2(Δ)s/2u22.

    We further have the following relation with the Fourier transform [[25], Proposition 3.3]

    (Δ)su=F1(|ξ|2s(F(u));

    notice that this last expression is suitable for defining the fractional Sobolev space Ws,p(RN) also for s1 and p1, by [28]

    Ws,p(RN)={uLp(RN)F1(|ξ|s(F(u))Lp(RN)}.

    Finally, set α(0,N), we recall the following standard estimates for the Riesz potential [[52], Theorem 4.3].

    Proposition 2.1 (Hardy-Littlewood-Sobolev inequality). Let α(0,N), and let r,h(1,+) be such that 1r1h=αN. Then the map

    fLr(RN)IαfLh(RN)

    is continuous. In particular, if r,t(1,+) verify 1r+1t=N+αN, then there exists a constant C=C(N,α,r,t)>0 such that

    |RN(Iαg)hdx|Cgrht

    for all gLr(RN) and hLt(RN).

    In this section we search for solutions to the fractional Choquard equation

    (Δ)su+μu=(IαF(u))f(u)inRN (3.1)

    by variational methods on the subspace of radially symmetric functions Hsr(RN). We recall that F=f and we assume (f1)–(f2) in order to have well defined functionals. We set D:Hsr(RN)R as

    D(u):=RN(IαF(u))F(u)dx

    and define the C1-functional Jμ:Hsr(RN)R associated to (3.1) by

    Jμ(u):=12RN|(Δ)s/2u|2dx12D(u)+μ2u22.

    We notice that, by the Principle of Symmetric Criticality of Palais, the critical points of Jμ are weak solutions of (3.1). Moreover, inspired by the Pohozaev identity

    N2s2(Δ)s/2u22+N2μu22=N+α2D(u) (3.2)

    we define also the Pohozaev functional Pμ:Hsr(RN)R by

    Pμ(u):=N2s2(Δ)s/2u22N+α2D(u)+N2μu22.

    Furthermore we introduce the set of paths

    Γμ:={γC([0,1],Hsr(RN))γ(0)=0,Jμ(γ(1))<0}

    and the Mountain Pass (MP for short) value

    l(μ):=infγΓμmaxt[0,1]Jμ(γ(t)). (3.3)

    Finally we set

    p(μ):=inf{Jμ(u)uHsr(RN){0},Pμ(u)=0}

    the least energy of Jμ on the Pohozaev set.

    Remark 3.1. Since of key importance in the good definition of the functionals, as well as in bootstrap argument in the rest of the paper, we write here in which spaces lie the considered quantities. Let uHs(RN)L2(RN)L2s(RN). By (f2) we have

    f(u)L2Nα(RN)LNα2NN2s(RN)+L2N2sα+2sL2Nα+2s(RN)L2Nα(RN)+L2Nα+2s(RN),F(u)L2NN+α(RN)LNN+α2NN2s(RN)+L2N2sN+α(RN)L2NN+α(RN)L2NN+α(RN).

    Thus by the Hardy-Littlewood-Sobolev inequality we obtain

    IαF(u)L2NNα(RN)L2N2N2(α+2s)N2sα(RN)+L2N(N2s)N2αN+4sα(RN)L2NNα(RN)L2NNα(RN).

    Finally, by the Hölder inequality, we have

    (IαF(u))f(u)L2(RN)L2N2N22sα(RN)+L2N(N2s)N2+2αs(RN)L2NN+2s(RN)L2(RN)+L2NN+2s(RN).

    In particular we observe that (IαF(u))f(u) does not lie in L2(RN), generally. On the other hand, if φHs(RN)L2(RN)L2s(RN), we notice that the found summability of (IαF(u))f(u) is enough to have

    RN(IαF(u))f(u)φdx

    well defined.

    We present now an existence result for (3.1).

    Theorem 3.2. Assume (f1)(f4). Let μ>0 be fixed. Then there exists a Mountain Pass solution u of (3.1), that is

    Jμ(u)=l(μ)>0.

    Moreover, the found solution satisfies the Pohozaev identity

    Pμ(u)=0.

    Proof. We split the proof in some steps.

    Step 1. We first show that Jμ satisfies the Palais-Smale-Pohozaev condition at every level bR, that is each sequence un in Hsr(RN) satisfying

    Jμ(un)b, (3.4)
    Jμ(un)0 stronglyin(Hsr(RN)), (3.5)
    Pμ(un)0, (3.6)

    converges up to a subsequence. Indeed (3.4) and (3.6) imply

    α+2s2(Δ)s/2un22+α2μun22=(N+α)b+o(1).

    Thus we obtain that b0 and un is bounded in Hsr(RN).

    Step 2. After extracting a subsequence, denoted in the same way, we may assume that unu0 weakly in Hsr(RN). Taking into account the assumptions (f1)–(f3), we obtain

    RN(IαF(un))f(un)u0dxRN(IαF(u0))f(u0)u0dx

    and

    RN(IαF(un))f(un)undxRN(IαF(u0))f(u0)u0dx.

    Thus we derive that Jμ(un),un0 and Jμ(un),u00, and hence

    (Δ)s/2un22+μun22(Δ)s/2u022+μu022

    which implies unu0 strongly in Hsr(RN).

    Step 3. Denote by

    [Jμb]:={uHsr(RN)Jμ(u)b}

    the sublevel of Jμ and by

    Kb:={uHsr(RN)Jμ(u)=b,Jμ(u)=0,Pμ(u)=0}

    the set of critical points of Jμ satisfying the Pohozaev identity. Then, by Steps 1–2, Kb is compact. Arguing as in [[40], Proposition 4.5] (see also [[43], Proposition 3.1 and Corollary 4.3]), we obtain for any bR, ˉε>0 and any U open neighborhood of Kb, that there exist an ε(0,ˉε) and a continuous map η:[0,1]×Hsr(RN)Hsr(RN) such that

    (1o) η(0,u)=uuHsr(RN);

    (2o) η(t,u)=u(t,u)[0,1]×[Jμbˉε];

    (3o) Jμ(η(t,u))Jμ(u) (t,u)[0,1]×Hsr(RN);

    (4o) η(1,[Jμb+ε]U)[Jμbε];

    (5o) η(1,[Jμb+ε])[Jμbε]U;

    (6o) if Kb=, then η(1,[Jμb+ε])[Jμbε].

    Step 4. By exploiting (f4) and arguing as in [[61], Proposition 2.1], we obtain the existence of a function vHsr(RN) such that D(v)>0. Thus defined γ(t):=v(/t) for t>0 and γ(0):=0 we have J(γ(t))<0 for t large and J(γ(t))>0 for t small; this means, after a suitable rescaling, that l(μ) is finite and strictly positive. In particular we observe that 0Kl(μ).

    Step 5. By applying the deformation result at level b=l(μ)>0, the existence of a Mountain Pass solution u is then obtained classically. Moreover, uKl(μ) by construction, thus u0 and Pμ(u)=0.

    We prove now that the found solution is actually a ground state over the Pohozaev set.

    Proposition 3.3. The Mountain Pass level and the Pohozaev minimum level coincide, that is

    l(μ)=p(μ)>0.

    In particular, the solution found in Theorem 3.2 is a Pohozaev minimum.

    Proof. Let uHsr(RN){0} such that Pμ(u)=0; observe that D(u)>0. We define γ(t):=u(/t) for t0 and γ(0):=0 so that t(0,+)Jμ(γ(t)) is negative for large values of t, and it attains the maximum in t=1. After a suitable rescaling we have γΓμ and thus

    Jμ(u)=maxt[0,1]Jμ(γ(t))l(μ). (3.7)

    Passing to the infimum in Eq (3.7) we have p(μ)l(μ). Let now γΓμ. By definition we have Jμ(γ(1))<0, thus by

    Pμ(v)=NJμ(v)s(Δ)s/2v22α2D(v),vHsr(RN),

    we obtain Pμ(γ(1))<0. In addition, since D(u)=o(uHs2) as u0 and γ(t)0 as t0 in Hsr(RN), we have

    Pμ(γ(t))>0forsmallt>0.

    Thus there exists a t such that Pμ(γ(t))=0, and hence

    p(μ)Jμ(γ(t))maxt[0,1]Jμ(γ(t));

    passing to the infimum we come up with p(μ)l(μ), and hence the claim.

    Proof of Theorem 1.1. We obtain the result by matching Theorem 3.2 and Proposition 3.3.

    We pass to investigate more in details Pohozaev minima, showing that it is a general fact that they are solutions of the Eq (3.1).

    Proposition 3.4. Every Pohozaev minimum is a solution of (3.1), i.e.,

    Jμ(u)=p(μ)andPμ(u)=0

    imply

    Jμ(u)=0.

    As a consequence

    p(μ)=inf{Jμ(u)uHsr(RN){0},Pμ(u)=0,Jμ(u)=0}.

    Proof. Let u be such that Jμ(u)=p(μ) and Pμ(u)=0. In particular, considered γ(t)=u(/t), we have that Jμ(γ(t)) is negative for large values of t and its maximum value is p(μ) attained only in t=1.

    Assume by contradiction that u is not critical. Let I:=[1δ,1+δ] be such that γ(I)Kp(μ)=, and set ˉε:=p(μ)maxtIJμ(γ(t))>0. Let now U be a neighborhood of Kp(μ) verifying γ(I)U=: by the deformation lemma presented in the proof of Theorem 3.2 there exists an η:[0,1]×Hsr(RN)Hsr(RN) at level p(μ)R with properties (1o)-(6o). Define then ˜γ(t):=η(1,γ(t)) a deformed path.

    For tI we have Jμ(γ(t))<p(μ)ˉε, and thus by (2o) we gain

    Jμ(˜γ(t))=Jμ(γ(t))<p(μ)ˉε,fortI. (3.8)

    Let now tI: we have γ(t)U and Jμ(γ(t))p(μ)p(μ)+ε, thus by (4o) we obtain

    Jμ(˜γ(t))p(μ)ε. (3.9)

    Joining (3.8) and (3.9) we have

    maxt0Jμ(˜γ(t))<p(μ)=l(μ)

    which is an absurd, since after a suitable rescaling it results that ˜γΓμ, thanks to (3o).

    Remark 3.5. We point out that it is not known, even in the case of local nonlinearities [7], if

    p(μ)=inf{Jμ(u)uHsr(RN){0},Jμ(u)=0}.

    On the other hand, by assuming that every solution of (3.1) satisfies the Pohozaev identity (see e.g., [[67], Proposition 2] and [[23], Eq (6.1)]), the claim holds true.

    We show now that, under the same assumptions of Theorem 3.2, we can find a solution with constant sign.

    Proposition 3.6. Assume (f1)(f4) and that F0 on (0,+) (i.e., t0 in assumption (f4) can be chosen positive). Then there exists a positive radially symmetric solution of (3.1), which is minimum over all the positive functions on the Pohozaev set.

    Proof. Let us define

    g:=χ(0,+)f.

    We have that g still satisfies (f1)–(f4). Thus, by Theorem 3.2 there exists a solution u of

    (Δ)su+μu=(IαG(u))g(u)inRN

    where G(t):=t0g(τ)dτ. We show now that u is positive. We start observing the following: by (2.2) we have

    (Δ)s/2|u|22=C(N,s)R2N(|u(x)||u(y)|)2|xy|N+2sdxdy=C(N,s)R2N|u|2(x)+|u|2(y)2|u|(x)|u|(y)|xy|N+2sdxdyC(N,s)R2Nu2(x)+u2(y)2u(x)u(y)|xy|N+2sdxdy=C(N,s)R2N(u(x)u(y))2|xy|N+2sdxdy=(Δ)s/2u22,

    thus

    (Δ)s/2|u|2(Δ)s/2u2.

    In particular, written u=u+u, by the previous argument we have u=|u|u2Hsr(RN). Thus, chosen u as test function, we obtain

    RN(Δ)s/2u(Δ)s/2udx+μRNuudx=RN(IαG(u))g(u)udx.

    By definition of g and (2.2) we have

    CN,sRN×RN(u(x)u(y))(u(x)u(y))|xy|N+2sdxdyμRNu2dx=0. (3.10)

    Splitting the domain, we gain

    RN×RN(u(x)u(y))(u(x)u(y))|xy|N+2sdxdy={u(x)0}×{u(y)<0}(u+(x)+u(y))(u(y))|xy|N+2sdxdy{u(x)<0}×{u(y)0}(u(x)+u+(y))(u(x))|xy|N+2sdxdy{u(x)<0}×{u(y)<0}(u(x)u(y))2|xy|N+2sdxdy.

    Thus we obtain that the left-hand side of (3.10) is sum of non positive pieces, thus u0, that is u0. Hence g(u)=f(u) and G(u)=F(u), which imply that u is a (positive) solution of (3.1).

    In this section we prove some regularity results for (3.1). We split the proof of Theorem 1.2 in different steps.

    We start from the following lemma, that can be found in [[61], Lemma 3.3].

    Lemma 4.1 ([61]). Let N2 and α(0,N). Let λ[0,2] and q,r,h,k[1,+) be such that

    1+αN1h1k=λq+2λr.

    Let θ(0,2) satisfying

    min{q,r}(αN1h)<θ<max{q,r}(11h),
    min{q,r}(αN1k)<2θ<max{q,r}(11k).

    Let HLh(RN), KLk(RN) and uLq(RN)Lr(RN). Then

    RN(Iα(H|u|θ))K|u|2θdxCHhKkuλqu2λr

    for some C>0 (depending on θ).

    By a proper use of Lemma 4.1 we obtain now an estimate on the Choquard term depending on Hs-norm of the function.

    Lemma 4.2. Let N2, s(0,1) and α(0,N). Let moreover θ(αN,2αN) and H,KL2Nα(RN)+L2Nα+2s(RN). Then for every ε>0 there exists Cε,θ>0 such that

    RN(Iα(H|u|θ))K|u|2θdxε2(Δ)s/2u22+Cε,θu22

    for every uHs(RN).

    Proof. Observe that 2θ(αN,2αN) as well. We write

    H=H+HL2Nα(RN)+L2Nα+2s(RN),
    K=K+KL2Nα(RN)+L2Nα+2s(RN).

    We split RN(Iα(H|u|θ))K|u|2θdx in four pieces and choose

    q=r=2,h=k=2Nα,λ=2,
    q=2,r=2NN2s,h=2Nα,k=2Nα+2s,λ=1,
    q=2,r=2NN2s,h=2Nα+2s,k=2Nα,λ=1,
    q=r=2NN2s,h=k=2Nα+2s,λ=0,

    in Lemma 4.1, to obtain

    RN(Iα(H|u|θ))K|u|2θdxH2NαK2Nαu22+H2NαK2Nα+2su2u2NN2s++H2Nα+2sK2Nαu2u2NN2s+H2Nα+2sK2Nα+2su22NN2s.

    Recalled that 2NN2s=2s and the Sobolev embedding (2.1), we obtain

    RN(Iα(H|u|θ))K|u|2θdx(H2NαK2Nα)u22+(H2Nα+2sK2Nα+2s)(Δ)s/2u22++(H2NαK2Nα+2s+H2Nα+2sK2Nα)u2(Δ)s/2u2, (4.1)

    where denotes an inequality up to a constant. We want to show now that, since 2Nα>2Nα+2s, we can choose the decomposition of H and K such that the L2Nα+2s-pieces are arbitrary small (see [[8], Lemma 2.1]). Indeed, let

    H=H1+H2L2Nα(RN)+L2Nα+2s(RN)

    be a first decomposition. Let M>0 to be fixed, and write

    H=(H1+H2χ{|H2|M})+H2χ{|H2|>M}.

    Since H2χ{|H2|M}L2Nα+2s(RN)L(RN) and 2Nα(2Nα+2s,), we have H2χ{|H2|M}L2Nα(RN), and thus

    H:=H1+H2χ{|H2|M}L2Nα(RN),H:=H2χ{|H2|>M}L2Nα+2s(RN).

    On the other hand

    H2Nα+2s=(|H2|>M|H2|2Nα+2sdx)α+2s2N

    which can be made arbitrary small for M0. In particular we choose the decomposition so that

    (H2Nα+2sK2Nα+2s)ε2

    and thus

    C(ε):≈(H2NαK2Nα).

    In the last term of (4.1) we use the generalized Young's inequality abδ2a2+12δb2, with

    δ:=ε2(H2NαK2Nα+2s+H2Nα+2sK2Nα)1

    so that

    (H2NαK2Nα+2s+H2Nα+2sK2Nα)u2(Δ)s/2u212ε2u22+C(ε)(Δ)s/2u22.

    Merging the pieces, we have the claim.

    The following technical result can be found in [[35], Lemma 3.5].

    Lemma 4.3 ([35]). Let a,bR, r2 and k0. Set Tk:R[k,k] the truncation in k, that is

    Tk(t):={kiftk,tift(k,k),kiftk,

    and write ak:=Tk(a), bk:=Tk(b). Then

    4(r1)r2(|ak|r/2|bk|r/2)2(ab)(ak|ak|r2bk|bk|r2).

    Notice that the (optimal) Sobolev embedding tells us that Hs(RN)L2s(RN). In the following we show that u belongs to some Lr(RN) with r>2s=2NN2s; we highlight that we make no use of the Caffarelli-Silvestre s-harmonic extension method, and work directly in the fractional framework.

    Proposition 4.4. Let H,KL2Nα(RN)+L2Nα+2s(RN). Assume that uHs(RN) solves

    (Δ)su+u=(Iα(Hu))K,inRN

    in the weak sense. Then

    uLr(RN)forallr[2,Nα2NN2s).

    Moreover, for each of these r, we have

    urCru2

    with Cr>0 not depending on u.

    Proof. By Lemma 4.2 there exists λ>0 (that we can assume large) such that

    RN(Iα(H|u|))K|u|dx12(Δ)s/2u22+λ2u22. (4.2)

    Let us set

    Hn:=Hχ{|H|n},Kn:=Kχ{|K|n},fornN

    and observe that

    Hn,KnL2Nα(RN),
    HnH,KnKalmosteverywhere,asn+

    and

    |Hn||H|,|Kn||K|foreverynN. (4.3)

    We thus define the bilinear form

    an(φ,ψ):=RN(Δ)s/2φ(Δ)s/2ψdx+λRNφψdxRN(Iα(Hnφ))Knψdx

    for every φ,ψHs(RN). Since, by (4.3) and (4.2), we have

    an(φ,φ)12(Δ)s/2φ22+λ2φ2212φ2Hs(RN) (4.4)

    for each φHs(RN), we obtain that an is coercive. Set

    f:=(λ1)uHs(RN)

    we obtain by Lax-Milgram theorem that, for each nN, there exists a unique unHs(RN) solution of

    an(un,φ)=(f,φ)2,φHs(RN),

    that is

    (Δ)sun+λun(Iα(Hnun))Kn=(λ1)u,inRN (4.5)

    in the weak sense; moreover the theorem tells us that

    unHsf21/2=2(λ1)u2

    (since 1/2 appears as coercivity coefficient in (4.4)), and thus un is bounded. Hence unˉu in Hs(RN) up to a subsequence for some ˉu. This means in particular that unˉu almost everywhere pointwise.

    Thus we can pass to the limit in

    RN(Δ)s/2un(Δ)s/2φdx+λRNunφdxRN(Iα(Hnun))Knφdx=(λ1)RNuφdx;

    we need to check only the Choquard term. We first see by the continuous embedding that unˉu in Lq(RN), for q[2,2s]. Split again H=H+H, K=K+K and work separately in the four combinations; we assume to work generally with ˜H{H,H}, ˜HLβ(RN) and ˜K{K,K}, ˜KLγ(RN), where β,γ{2Nα,2Nα+2s}. Then one can easily prove that ˜Hnun˜Hˉu in Lr(RN) with 1r=1β+1q. By the continuity and linearity of the Riesz potential we have Iα(Hnun)Iα(Hˉu) in Lh(RN), where 1h=1rαn. As before, we obtain (Iα(Hnun))Kn(Iα(Hˉu))K in Lk(RN), where 1k=1γ+1h. Simple computations show that if β=γ=2Nα and q=2, then k=2; if β=2Nα, γ=2Nα+2s (or viceversa) and q=2, then k=2s; if β=γ=2Nα+2s and q=2s, then k=2s. Therefore Hs(RN)Lk(RN) and we can pass to the limit in all the four pieces, obtaining

    RN(Iα(Hnun))KnφdxRN(Iα(Hˉu))Kφdx.

    Therefore, ˉu satisfies

    (Δ)sˉu+λˉu(Iα(Hˉu))K=(λ1)u,inRN

    as well as u. But we can see this problem, similarly as before, with a Lax-Milgram formulation and obtain the uniqueness of the solution. Thus ˉu=u and hence

    unuinHs(RN),asn+

    and almost everywhere pointwise. Let now k0 and write

    un,k:=Tk(un)L2(RN)L(RN)

    where Tk is the truncation introduced in Lemma 4.3. Let r2. We have |un,k|r/2Hs(RN), by exploiting (2.2) and the fact that h(t):=(Tk(t))r/2 is a Lipschitz function with h(0)=0. By (2.2) and by Lemma 4.3 we have

    4(r1)r2RN|(Δ)s/2(|un,k|r/2)|2dx=C(N,s)R2N4(r1)r2(|un,k(x)|r/2|un,k(y)|r/2)2|xy|N+2sdxdyC(N,s)R2N(un(x)un(y))(un,k(x)|un,k(x)|r2un,k(y)|un,k(y)|r2)|xy|N+2sdxdy.

    Set

    φ:=un,k|un,k|r2

    it results that φHs(RN), since again h(t):=Tk(t)|Tk(t)|r2 is a Lipschitz function with h(0)=0. Thus we can choose it as a test function in (4.5) and obtain, by polarizing the identity (2.2),

    4(r1)r2RN|(Δ)s/2(|un,k|r/2)|2dxC(N,s)R2N(un(x)un(y))(φ(x)φ(y))|xy|N+2sdxdy=λRNunφdx+RN(Iα(Hnun))Knφdx+(λ1)RNuφdx

    and since unφ|un,k|r we gain

    4(r1)r2N|(Δ)s/2(|un,k|r/2)|2dxλN|un,k|rdx+N(Iα(Hnun))Knφdx+(λ1)Nuφdx. (4.6)

    Focus on the Choquard term on the right-hand side. We have

    RN(Iα(Hnun))Knφdx (4.7)
    RN(Iα(|Hn||un|χ{|un|k}))|Kn||un,k|r1dx+RN(Iα(|Hn||un|χ{|un|>k}))|Kn||un,k|r1dxRN(Iα(|Hn||un,k|))|Kn||un,k|r1dx+RN(Iα(|Hn||un|χ{|un|>k}))|Kn||un|r1dx(4.3)RN(Iα(|H||un,k|))|K||un,k|r1dx+RN(Iα(|Hn||un|χ{|un|>k}))|Kn||un|r1dx=(I)+(II). (4.8)

    Focus on (I). Consider r[2,2Nα), so that θ:=2r(αN,2αN). Choose moreover v:=|un,k|r/2Hs(RN) and ε2:=2(r1)r2>0. Thus, observed that if a function belongs to a sum of Lebesgue spaces then its absolute value does the same ([[3], Proposition 2.3]), by Lemma 4.2 we obtain

    (I)2(r1)r2(Δ)s/2(|un,k|r/2)22+C(r)|un,k|r/222. (4.9)

    Focus on (II). Assuming r<min{2Nα,2NN2s}, we have unLr(RN) and HnL2Nα(RN), thus

    |Hn||un|La(RN),with1a=α2N+1r

    for the Hölder inequality. Similarly

    |Kn||un|r1Lb(RN),with1b=α2N+11r.

    Thus, since 1a+1b=N+αN, we have by the Hardy-Littlewood-Sobolev inequality (see Proposition 2.1) that

    RN(Iα(|Hn||un|χ{|un|>k}))|Kn||un|r1dxC({|un|>k}||Hn||un||adx)1/a(RN||Kn||un|r1|bdx)1/b.

    With respect to k, the second factor on the right-hand side is bounded, while the first factor goes to zero thanks to the dominated convergence theorem, thus

    (II)=ok(1),ask+. (4.10)

    Joining (4.6), (4.8), (4.9), (4.10) we obtain

    2(r1)r2RN|(Δ)s/2(|un,k|r/2)|2dxλRN|un,k|rdx+C(r)RN|un,k|rdx+(λ1)RNuφdx+ok(1).

    That is, by Sobolev inequality (2.1)

    C(r)(RN|un,k|r22sdx)2/2s(C(r)λ)RN|un,k|rdx+(λ1)RN|u||un,k|r1dx+ok(1).

    Letting k+ by the monotone convergence theorem (since un,k are monotone with respect to k and un,kun pointwise) we have

    C(r)(RN|un|r22sdx)2/2s(C(r)λ)RN|un|rdx+(λ1)RN|u||un|r1dx (4.11)

    and thus unLr22s(RN). Notice that r2[1,min{Nα,NN2s}). If N2s<α we are done. Otherwise, set r1:=r, we can now repeat the argument with

    r2(2NN2s,min{2Nα,2(NN2s)2}).

    Again, if 2Nα<2(NN2s)2 we are done, otherwise we repeat the argument. Inductively, we have

    (NN2s)m+,asm+

    thus 2Nα<2(NN2s)m after a finite number of steps. For such r=rm, consider again (4.11): by the almost everywhere convergence of un to u and Fatou's lemma

    C(r)(RN|u|r22s)2/2sdxlim infnC(r)(RN|un|r22sdx)2/2slim infn((C(r)λ)RN|un|rdx+(λ1)RN|u||un|r1dx)(C(r)λ)lim supnRN|un|rdx+(λ1)lim supnRN|u||un|r1dx.

    Being un equibounded in Hs(RN) and thus in L2s(RN), by the iteration argument we have that it is equibounded also in Lr(RN); in particular, the bound is given by u2 times a constant C(r). Thus the right-hand side is a finite quantity, and we gain uLr22s(RN), which is the claim.

    The following Lemma states that IαgL(RN) whenever g lies in Lq(RN) with q in a neighborhood of Nα (in particular, it generalizes Proposition 2.1 to the case h= and rNα).

    In addition, it shows the decay at infinity of the Riesz potential, which will be useful in Section 5.

    Proposition 4.5. Assume that (f1)–(f2) hold. Let uHs(RN) be a solution of (3.1). Then uLq(RN) for q[2,Nα2NN2s), and

    IαF(u)C0(RN),

    that is, continuous and zero at infinity. In particular,

    IαF(u)L(RN)

    and

    (IαF(u))(x)0as|x|+.

    Proof. We first check to be in the assumptions of Proposition 4.4. Indeed, by (f1)–(f2) and the fact that uHs(RN)L2(RN)L2s(RN) we obtain that

    H:=F(u)u,K:=f(u)

    lie in L2Nα(RN)+L2Nα+2s(RN), since bounded by functions in this sum space (see e.g., [[3], Proposition 2.3]). Now by Proposition 4.4 we have uLq(RN) for q[2,Nα2NN2s).

    To gain the information on the convolution, we want to use Young's Theorem, which states that if g,h belong to two Lebesgue spaces with conjugate (finite) indexes, then ghC0(RN). We first split

    IαF(u)=(IαχB1)F(u)+(IαχBc1)F(u)

    where

    IαχB1Lr1(RN),forr1[1,NNα),
    IαχBc1Lr2(RN),forr2(NNα,].

    We need to show that F(u)Lq1(RN)Lq2(RN) for some qi satisfying

    1qi+1ri=1,i=1,2

    that is

    q1q11[1,NNα),q2q21(NNα,]

    or equivalently q2<Nα<q1. Recall that

    |F(u)|C(|u|N+αN+|u|N+αN2s).

    Note that uLq(RN) for q[2,Nα2NN2s) implies

    |u|N+αN,|u|N+αN2sLq1(RN)Lq2(RN)

    for some q2<Nα<q1. Thus we have the claim.

    Once obtained the boundedness of the Choquard term, we can finally gain the boundedness of the solution.

    Proposition 4.6. Assume that (f1)–(f2) hold. Let uHs(RN) be a positive solution of (3.1). Then uL(RN).

    Proof. By Lemma 4.5 we obtain

    a:=IαF(u)L(RN).

    Thus u satisfies the following nonautonomous problem, with a local nonlinearity

    (Δ)s/2u+μu=a(x)f(u),inRN

    with a bounded. In particular

    (Δ)s/2u=g(x,u):=μu+a(x)f(u),inRN

    where

    |g(x,t)|μ|t|+Ca(|t|αN+|t|α+2sN2s).

    Set γ:=max{1,α+2sN2s}[1,2s), we thus have

    |g(x,t)|C(1+|t|γ).

    Hence we are in the assumptions of [[26], Proposition 5.1.1] and we can conclude.

    We observe that a direct proof of the boundedness for generally signed solutions, but assuming also (f5), can be found in Appendix A.

    Gained the boundedness of the solutions, we obtain also some additional regularity, which will be implemented in some bootstrap argument for the L1-summability.

    Proposition 4.7. Assume that (f1)–(f2) hold. Let uHs(RN)L(RN) be a weak solution of (3.1). Then uH2s(RN)C0,γ(RN) for any γ(0,min{1,2s}). Moreover u satisfies (3.1) almost everywhere.

    Proof. By Proposition 4.6, Proposition 4.5 and (f2) we have that uL(RN) satisfies

    (Δ)su=gL(RN)

    where g(x):=μu(x)+(IαF(u))(x)f(u(x)). We prove first that uH2s(RN). Indeed, we already know that f(u), F(u) and IαF(u) belong to L(RN). By Remark 3.1, we obtain

    f(u)L2Nα+2s(RN)L(RN),F(u)L2NN+α(RN)L(RN),
    IαF(u)L2NN2s(RN)L(RN),(IαF(u))f(u)L2(RN)L(RN).

    In particular,

    g:=(IαF(u))f(u)μuL2(RN).

    Since u is a weak solution, we have, fixed φHs(RN),

    RN(Δ)s/2u(Δ)s/2φdx=RNgφdx. (4.12)

    Since gL2(RN), we can apply Plancharel theorem and obtain

    RN|ξ|2sˆuˆφdξ=RNˆgˆφdξ. (4.13)

    Since Hs(RN)=F(Hs(RN)) and φ is arbitrary, we gain

    |ξ|2sˆu=ˆgL2(RN).

    By definition, we obtain uH2s(RN), which concludes the proof. Observe moreover that F1((1+|ξ|2s)ˆu)=u+gL2(RN)L(RN), thus by definition uH2s(RN)W2s,(RN). By the embedding [[28], Theorem 3.2] we obtain uC0,γ(RN) if 2s<1 and γ(0,2s), while uC1,γ(RN) if 2s>1 and γ(0,2s1) (see also [[68], Proposition 2.9]).

    It remains to show that u is an almost everywhere pointwise solution. Thanks to the fact that uH2s(RN), we use again (4.13), where we can apply Plancharel theorem (that is, we are integrating by parts (4.12)) and thus

    RN(Δ)suφdx=RNgφdx.

    Since φHs(RN) is arbitrary, we obtain

    (Δ)su=galmosteverywhere.

    This concludes the proof.

    We observe, by the proof, that if s(12,1), then uC1,γ(RN) for any γ(0,2s1), and u is a classical solution, with (Δ)suC(RN) and equation (3.1) satisfied pointwise.

    We end this section by dealing with the summability of u in Lebesgue spaces Lr(RN) for r<2.

    Remark 4.8. We start noticing that, if a solution u belongs to some Lq(RN) with q<2, then uL1(RN). Assume thus q(1,2) and let uLq(RN)L(RN), then we have

    f(u)LqNα(RN)L(RN),F(u)LqNN+α(RN)L(RN),
    IαF(u)LqNN+α(1q)(RN)L(RN),(IαF(u))f(u)LqNN+α(2q)(RN)L(RN).

    Thanks to Proposition 4.7, u satisfies (3.1) almost everywhere, thus we have

    F1((|ξ|2s+μ)ˆu)=(Δ)su+μu=(IαF(u))f(u)LqNN+α(2q)(RN)

    which equivalently means that the Bessel operator verifies

    F1((|ξ|2+1)sˆu)LqNN+α(2q)(RN).

    Thus by [[2], Theorem 1.2.4] we obtain that u itself lies in the same Lebesgue space, that is

    uLqNN+α(2q)(RN).

    If qNN+α(2q)<1, we mean that (IαF(u))f(u)L1(RN)L(RN), and thus uL1(RN)L(RN). We convey this when we deal with exponents less than 1.

    If q<2, then

    qNN+α(2q)<q

    and we can implement a bootstrap argument to gain uL1(RN). More precisely

    {q0[1,2)qn+1=qnNN+α(2qn)

    where qn0 (but we stop at 1). Thus, in order to implement the argument, we need to show that uLq(RN) for some q<2.

    We show now that uL1(RN). It is easy to see that, if the problem is (strictly) not lower-critical, i.e., (f2) holds together with

    limt0F(t)|t|β=0

    for some β(N+αN,N+αN2s), then uL1(RN). Indeed uHs(RN)L(RN)L2(RN)L(RN) and

    (IαF(u))f(u)Lq(RN),

    where 1q=β2α2N; noticed that q<2, we can implement the bootstrap argument of Remark 4.8.

    We will show that the same conclusion can be reached by assuming only (f2).

    Proposition 4.9. Assume that (f1)(f2) hold. Let uHs(RN)L(RN) be a weak solution of (3.1). Then uL1(RN).

    Proof of Proposition 4.9. For a given solution uHs(RN)L(RN) we set again

    H:=F(u)u,K:=f(u).

    Since uL2(RN)L(RN), by (f2) we have H, KL2Nα(RN). For nN, we set

    Hn:=Hχ{|x|n}.

    Then we have

    Hn2Nα0asn. (4.14)

    Since supp(HHn){|x|n} is a bounded set, we have for any β[1,2Nα]

    HHnLβ(RN)forallnN. (4.15)

    We write our equation (3.1) as

    (Δ)su+μu=(IαHnu)K+RninRN,

    where we introduced the function Rn by

    Rn:=(Iα(HHn)u)K.

    Now we consider the following linear equation:

    (Δ)sv+μv=(IαHnv)K+RninRN. (4.16)

    We have the following facts:

    (i) The given solution u solves (4.16).

    (ii) By the property (4.15) with β(2NN+α,2Nα), there exists q1(1,2), namely 1q1=1β+12α2N, such that RnLq1(RN)L2(RN).

    (iii) By the property (4.14), for any r(2N2Nα,2](1,2]

    vLr(RN)An(v):=(IαHnv)KLr(RN)

    is well-defined and verifies

    An(v)rCr,nvr. (4.17)

    Here Cr,n satisfies Cr,n0 as n.

    We show only (iii). Since vLr(RN), by Hardy-Littlewood-Sobolev inequality and Hölder inequality we obtain

    An(v)rCrHn2NαK2Nαvr,

    where Cr>0 is independent of n, v. Thus by (4.14) we have Cr,n:=CrHn2NαK2Nα0 as n.

    Now we show uLq1(RN), where q1(1,2) is given in (ii). Since ((Δ)s+μ)1:Lr(RN)Lr(RN) is a bounded linear operator for r(1,2] (see [[2], Theorem 1.2.4]), (4.16) can be rewritten as

    v=Tn(v),

    where

    Tn(v):=((Δ)s+μ)1(An(v)+Rn).

    By choosing β(2,2Nα) we have q1(2N2Nα,2)(1,2), thus we observe that for n large, Tn is a contraction in L2(RN) and in Lq1(RN). We fix such an n.

    Since Tn is a contraction in L2(RN), we can see that uHs(RN) is a unique fixed point of Tn. In particular, we have

    u=limkTkn(0)in L2(RN).

    On the the other hand, since Tn is a contraction in Lq1(RN), (Tkn(0))k=1 also converges in Lq1(RN). Thus the limit u belongs to Lq1(RN).

    Since q1<2 we can use the bootstrap argument of Remark 4.8 to get uL1(RN), and reach the claim.

    We prove now the polynomial decay of the solutions. We start from two standard lemmas, whose proofs can be found for instance in [[15], Lemma A.1 and Lemma A.3].

    Lemma 5.1 (Maximum Principle). Let ΣRN, possibly unbounded, and let uHs(RN) be a weak subsolution of

    (Δ)su+au0inRNΣ

    with a>0, in the sense that

    RN(Δ)s/2u(Δ)s/2φdx+aRNuφdx0

    for every positive φHs(RN) with supp(φ)RNΣ. Assume moreover that

    u0,fora.e.xΣ.

    Then

    u0,fora.e.xRN. (5.1)

    Lemma 5.2 (Comparison function). Let b>0. Then there exists a strictly positive continuous function WHs(RN) such that, for some positive constants C,C (depending on b), it verifies

    (Δ)sW+bW=0inRNBr

    pointwise, with r:=b1/2s, and

    C|x|N+2s<W(x)<C|x|N+2s,for|x|>2r. (5.2)

    We show first some conditions which imply the decay at infinity of the solutions.

    Lemma 5.3. Assume that (f1)–(f2) hold. Let u be a weak solution of (3.1). Assume

    uLN2s(RN)L(RN)

    and

    (IαF(u))f(u)LN2s(RN)L(RN).

    Then we have

    u(x)0as|x|+. (5.3)

    Proof. Being u solution of

    (Δ)su+u=(1μ)u+(IαF(u))f(u)=:χinRN,

    where χLN2s(RN)L(RN), we have the representation formula

    u=Kχ

    where K is the Bessel kernel; we recall that K is positive, it satisfies K(x)C|x|N+2s for |x|1 and KLq(RN) for q[1,1+2sN2s) (see [[28], page 1241 and Theorem 3.3]). Let us fix η>0; we have, for xRN,

    u(x)=RNK(xy)χ(y)dy=|xy|1/ηK(xy)χ(y)dy+|xy|<1/ηK(xy)χ(y)dy.

    As regards the first piece

    |xy|1/ηK(xy)χ(y)dyχ|xy|1/ηC|xy|N+2sdyCη2s

    while for the second piece, fixed a whatever q(1,1+2sN2s) and its conjugate exponent q>N2s, we have by Hölder inequality

    |xy|<1/ηK(xy)χ(y)dyKqχLq(B1/η(x))

    where the second factor can be made small for |x|0. Joining the pieces, we have (5.3).

    We observe that the assumptions of the Lemma are fulfilled by assuming that u is bounded thanks to Proposition 4.9. We are now ready to prove the polynomial decay of the solutions.

    Conclusion of the proof of Theorem 1.3. Observe that, by (f5) and Lemma 5.3, we have

    f(u)uL(RN). (5.4)

    Thus we obtain, by applying Proposition 4.5, that

    (IαF(u))(x)f(u(x))u(x)0as|x|+. (5.5)

    Thus, by (5.5) and the positivity of u, we have for some R0

    (Δ)su+12μu=(IαF(u))f(u)12μu=((IαF(u))f(u)u12μ)u0inRNBR.

    Similarly

    (Δ)su+32μu=(IαF(u))f(u)+12μu=((IαF(u))f(u)u+12μ)u0inRNBR.

    Notice that we always intend differential inequalities in the weak sense, that is tested with functions in Hs(RN) with supports contained in the reference domain (e.g., RNBR).

    In addition, by Lemma 5.2 we have that there exist two positive functions W_, ¯W and three positive constants R, C and C depending only on μ, such that

    {(Δ)sW_+32μW_=0inRNBR,C|x|N+2s<W_(x),for|x|>2R.

    and

    {(Δ)s¯W+12μ¯W=0inRNBR,¯W(x)<C|x|N+2s,for|x|>2R.

    Set R:=max{R,2R}. Let C_1 and ¯C1 be some lower and upper bounds for u on BR, C_2:=minBR¯W and ¯C2:=maxBRW_, all strictly positive. Define

    W_:=C_1¯C12W_,¯W:=¯C1C_12¯W

    so that

    W_(x)u(x)¯W(x),for|x|R.

    Thanks to the comparison principle in Lemma 5.1, and redefining C and C, we obtain

    C|x|N+2s<W_(x)u(x)¯W(x)<C|x|N+2s,for|x|>R.

    By the boundedness of u, we obtain the claim.

    We see that, for non sublinear f (that is, (f5)), the decay is essentially given by the fractional operator. It is important to remark that, contrary to the limiting local case s=1 (see [60]), the Choquard term in case of linear f does not affect the decay of the solution.

    Remark 5.4. We observe that the conclusion of the proof of Theorem 1.3 can be substituted by exploiting a result in [30]. Indeed write V:=(IαF(u))f(u)u, which is bounded and zero at infinity as observed in (5.4)–(5.5), and gain

    (Δ)su+V(x)u=μuinRN.

    Up to dividing for u2, we may assume u2=1. Thus we are in the assumptions of [[30], Lemma C.2] and obtain, even for changing-sign solutions of (3.1),

    |u(x)|C1(1+|x|2)N+2s2

    together with

    |u(x)|=C2|x|N+2s+o(1|x|N+2s)as|x|+

    for some C1,C2>0.

    The first and second authors are supported by PRIN 2017JPCAPN "Qualitative and quantitative aspects of nonlinear PDEs'' and by INdAM-GNAMPA. The third author is supported in part by Grant-in-Aid for Scientific Research (19H00644, 18KK0073, 17H02855, 16K13771) of Japan Society for the Promotion of Science.

    All authors declare no conflicts of interest in this paper.



    Conflict of interest



    All authors declare no conflict of interest

    [1] Fiorino S, Tateo F, Biase D, et al. (2021) SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses. Future Microbiol 16: 1105-1133. https://doi.org/10.2217/fmb-2021-0064
    [2] Fares A (2013) Factors influencing the seasonal patterns of infectious diseases. Int J Prev Med 4: 128-132.
    [3] Price RHM, Graham C, Ramalingam S (2019) Association between viral seasonality and meteorological factors. Sci Rep 9: 929. https://doi.org/10.1038/s41598-018-37481-y
    [4] Juthani PV, Gupta A, Borges KA, et al. (2021) Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis 21: 1485-1486. https://doi.org/10.1016/S1473-3099(21)00558-2
    [5] Rivasi G, Bulgaresi M, Mossello E, et al. (2021) Course and Lethality of SARS-CoV-2 Epidemic in Nursing Homes after Vaccination in Florence, Italy. Vaccines (Basel) 9: 1174. https://doi.org/10.3390/vaccines9101174
    [6] COVID-19 vaccine effectiveness. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/
    [7] Afrough B, Dowall S, Hewson R (2019) Emerging viruses and current strategies for vaccine intervention. Clin Exp Immunol 196: 157-166. https://doi.org/10.1111/cei.13295
    [8] Calina D, Docea AO, Petrakis D, et al. (2020) Towards effective COVID19 vaccines: Updates, perspectives and challenges (Review). Int J Mol Med 46: 3-16. https://doi.org/10.3892/ijmm.2020.4596
    [9] Castro C, Arnold JJ, Cameron CE (2005) Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res 107: 141-149. https://doi.org/10.1016/j.virusres.2004.11.004
    [10] Smith DB, Bukh J, Kuiken C, et al. (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59: 318-327. https://doi.org/10.1002/hep.26744
    [11] Yuan M, Huang D, Lee CD, et al. (2021) Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science 373: 818-823. https://doi.org/10.1126/science.abh1139
    [12] Yewdell JW (2021) Antigenic drift: Understanding COVID-19. Immunity 54: 2681-2687. https://doi.org/10.1016/j.immuni.2021.11.016
    [13] Vasireddy D, Vanaparthy R, Mohan G, et al. (2021) Review of COVID-19 variants and COVID-19 vaccine efficacy: What the clinician should know?. J Clin Med Res 13: 317-325. https://doi.org/10.14740/jocmr4518
    [14] Hodgson SH, Mansatta K, Mallett G, et al. (2021) What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 21: e26-e35. https://doi.org/10.1016/S1473-3099(20)30773-8
    [15] Andrews N, Tessier E, Stowe J, et al. (2021) Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv . https://doi.org/10.1101/2021.09.15.21263583
    [16] Bergwerk M, Gonen T, Lustig Y, et al. (2021) Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med 385: 1474-1484. https://doi.org/10.1056/NEJMoa2109072
    [17] Cohn BA, Cirillo PM, Murphy CC, et al. (2022) SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science 375: 331-336. https://doi.org/10.1126/science.abm0620
    [18] Rzymski P, Camargo CA, Fal A, et al. (2021) COVID-19 vaccine boosters: The good, the bad, and the ugly. Vaccines (Basel) 9: 1299. https://doi.org/10.3390/vaccines9111299
    [19] Gazit S, Mizrahi B, Kalkstein N, et al. (2021) BNT162b2 mRNA vaccine effectiveness given confirmed exposure: Analysis of household members of COVID-19 patients. Clin Infect Dis 75: e73-e740. https://doi.org/10.1093/cid/ciab973
    [20] Chen X, Wang W, Chen X, et al. (2022) Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint. BMC Med 20: 36. https://doi.org/10.1186/s12916-022-02249-9
    [21] Levin EG, Lustig Y, Cohen C, et al. (2021) Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med 385: e84. https://doi.org/10.1056/NEJMoa2114583
    [22] Gao YD, Ding M, Dong X, et al. (2021) Risk factors for severe and critically ill COVID-19 patients: A review. Allergy 76: 428-455. https://doi.org/10.1111/all.14657
    [23] WHOCOVID-19: Booster Shots (2021). Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/science-in-5/episode-53---covid-19-booster-shots.
    [24] WHOCoronavirus disease (COVID-19): Vaccines (2022). Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-(covid-19)-vaccines
    [25] Bar-On YM, Goldberg Y, Mandel M, et al. (2021) Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 385: 1393-1400. https://doi.org/10.1056/NEJMoa2114255
    [26] Krause PR, Fleming TR, Peto R, et al. (2021) Considerations in boosting COVID-19 vaccine immune responses. Lancet 398: 1377-1380. https://doi.org/10.1016/S0140-6736(21)02046-8
    [27] Lam JH, Smith FL, Baumgarth N (2020) B cell activation and response regulation during viral infections. Viral Immunol 33: 294-306. https://doi.org/10.1089/vim.2019.0207
    [28] Laidlaw BJ, Craft JE, Kaech SM (2016) The multifaceted role of CD4(+) T cells in CD8(+) T cell memory. Nat Rev Immunol 16: 102-111. https://doi.org/10.1038/nri.2015.10
    [29] Kervevan J, Chakrabarti LA (2021) Role of CD4+ T cells in the control of viral infections: Recent advances and open questions. Int J Mol Sci 22: 523. https://doi.org/10.3390/ijms22020523
    [30] Sallusto F (2016) Heterogeneity of Human CD4(+) T cells against microbes. Annu Rev Immunol 34: 317-334. https://doi.org/10.1146/annurev-immunol-032414-112056
    [31] Altmann DM, Boyton RJ, Beale R (2021) Immunity to SARS-CoV-2 variants of concern. Science 371: 1103-1104. https://doi.org/10.1126/science.abg7404
    [32] Kramer B, Knoll R, Bonaguro L, et al. (2021) Early IFN-alpha signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity 54: 2650-2669 e2614. https://doi.org/10.1016/j.immuni.2021.09.002
    [33] Leem G, Cheon S, Lee H, et al. (2021) Abnormality in the NK-cell population is prolonged in severe COVID-19 patients. J Allergy Clin Immunol 148: 996-1006 e1018. doi:10.1016/j.jaci.2021.07.022
    [34] Peng Y, Mentzer AJ, Liu G, et al. (2020) Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol 21: 1336-1345. https://doi.org/10.1038/s41590-020-0782-6
    [35] Min YQ, Huang M, Sun X, et al. (2021) Immune evasion of SARS-CoV-2 from interferon antiviral system. Comput Struct Biotechnol J 19: 4217-4225. https://doi.org/10.1016/j.csbj.2021.07.023
    [36] Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. (2020) Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183: 996-1012 e1019. https://doi.org/10.1016/j.cell.2020.09.038
    [37] Tan AT, Linster M, Tan CW, et al. (2021) Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep 34: 108728. https://doi.org/10.1016/j.celrep.2021.108728
    [38] Carsetti R, Zaffina S, Piano Mortari E, et al. (2020) Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases. Front Immunol 11: 610300. https://doi.org/10.3389/fimmu.2020.610300
    [39] Jordan SC, Shin BH, Gadsden TM, et al. (2021) T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals. Cell Mol Immunol 18: 2554-2556. https://doi.org/10.1038/s41423-021-00767-9
    [40] Neidleman J, Luo X, George AF, et al. (2021) Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Cell Rep 36: 109414. https://doi.org/10.1016/j.celrep.2021.109414
    [41] Swadling L, Maini MK (2020) T cells in COVID-19 - united in diversity. Nat Immunol 21: 1307-1308. https://doi.org/10.1038/s41590-020-0798-y
    [42] Mileto D, Fenizia C, Cutrera M, et al. (2021) SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response. Emerg Microbes Infect 10: 2235-2243. https://doi.org/10.1080/22221751.2021.2004866
    [43] Neidleman J, Luo X, Frouard J, et al. (2020) SARS-CoV-2-Specific T cells exhibit phenotypic features of helper function, lack of terminal differentiation, and high proliferation potential. Cell Rep Med 1: 100081. https://doi.org/10.1016/j.xcrm.2020.100081
    [44] Yin SW, Zhou Z, Wang JL, et al. (2021) Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study. Virol J 18: 126. https://doi.org/10.1186/s12985-021-01597-x
    [45] Balachandran H, Phetsouphanh C, Agapiou D, et al. (2022) Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. Cell Rep 38: 110345. https://doi.org/10.1016/j.celrep.2022.110345
    [46] Gurevich M, Zilkha-Falb R, Sonis P, et al. (2022) SARS-CoV-2 memory B and T cell profiles in mild COVID-19 convalescent patients. Int J Infect Dis 115: 208-214. https://doi.org/10.1016/j.ijid.2021.12.309
    [47] Soresina A, Moratto D, Chiarini M, et al. (2020) Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol 31: 565-569. https://doi.org/10.1111/pai.13263
    [48] Zhao Q, Meng M, Kumar R, et al. (2020) Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. Int J Infect Dis 96: 131-135. https://doi.org/10.1016/j.ijid.2020.04.086
    [49] De Biasi S, Meschiari M, Gibellini L, et al. (2020) Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun 11: 3434. https://doi.org/10.1038/s41467-020-17292-4
    [50] Mathew D, Giles JR, Baxter AE, et al. (2020) Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369: eabc8511. https://doi.org/10.1126/science.abc8511
    [51] Zhang J, Lin H, Ye B, et al. (2021) One-year sustained cellular and humoral immunities of COVID-19 convalescents. Clin Infect Dis 75: e1072-e1081. https://doi.org/10.1093/cid/ciab884
    [52] Altman JD, Moss PA, Goulder PJ, et al. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96. https://doi.org/10.1126/science.274.5284.94
    [53] Maini MK, Boni C, Ogg GS, et al. (1999) Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 117: 1386-1396. https://doi.org/10.1016/S0016-5085(99)70289-1
    [54] Ogg GS, McMichael AJ (1998) HLA-peptide tetrameric complexes. Curr Opin Immunol 10: 393-396. https://doi.org/10.1016/S0952-7915(98)80110-6
    [55] Zhu F, Eckels DD (2002) Functionally distinct helper T-cell epitopes of HCV and their role in modulation of NS3-specific, CD8+/tetramer positive CTL. Hum Immunol 63: 710-718. https://doi.org/10.1016/S0198-8859(02)00430-5
    [56] Mondelli M, Vergani GM, Alberti A, et al. (1982) Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 129: 2773-2778.
    [57] Maini MK, Boni C, Lee CK, et al. (2000) The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191: 1269-1280. https://doi.org/10.1084/jem.191.8.1269
    [58] Walewska-Zielecka B, Madalinski K, Jablonska J, et al. (2008) Composition of inflammatory infiltrate and its correlation with HBV/HCV antigen expression. World J Gastroenterol 14: 4040-4046. https://doi.org/10.3748/wjg.14.4040
    [59] Wang H, Wu B, Li L, et al. (2017) Hepatic expansion of virus-specific CD8(+)BTLA(+) T cells with regulatory properties in chronic hepatitis B virus infection. Cell Immunol 311: 36-45. https://doi.org/10.1016/j.cellimm.2016.10.002
    [60] Welsh RM, Selin LK (2002) No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol 2: 417-426. https://doi.org/10.1038/nri820
    [61] Tough DF, Borrow P, Sprent J (1996) Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272: 1947-1950. https://doi.org/10.1126/science.272.5270.1947
    [62] Kim TS, Shin EC (2019) The activation of bystander CD8(+) T cells and their roles in viral infection. Exp Mol Med 51: 1-9. https://doi.org/10.1038/s12276-019-0316-1
    [63] van Aalst S, Ludwig IS, van der Zee R, et al. (2017) Bystander activation of irrelevant CD4+ T cells following antigen-specific vaccination occurs in the presence and absence of adjuvant. PLoS One 12: e0177365. https://doi.org/10.1371/journal.pone.0177365
    [64] Martin MD, Shan Q, Xue HH, et al. (2017) Time and antigen-stimulation history influence memory CD8 T cell bystander responses. Front Immunol 8: 634. https://doi.org/10.3389/fimmu.2017.00634
    [65] Zhang X, Sun S, Hwang I, et al. (1998) Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8: 591-599. https://doi.org/10.1016/S1074-7613(00)80564-6
    [66] Raue HP, Brien JD, Hammarlund E, et al. (2004) Activation of virus-specific CD8+ T cells by lipopolysaccharide-induced IL-12 and IL-18. J Immunol 173: 6873-6881. https://doi.org/10.4049/jimmunol.173.11.6873
    [67] Xu D, Fu J, Jin L, et al. (2006) Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177: 739-747. https://doi.org/10.4049/jimmunol.177.1.739
    [68] Wu W, Li J, Chen F, et al. (2010) Circulating Th17 cells frequency is associated with the disease progression in HBV infected patients. J Gastroenterol Hepatol 25: 750-757. https://doi.org/10.1111/j.1440-1746.2009.06154.x
    [69] Chen G, Wu D, Guo W, et al. (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130: 2620-2629. https://doi.org/10.1172/JCI137244
    [70] Datta U, Sehgal S, Pal SR, et al. (1982) Lymphocyte subpopulation in acute viral hepatitis. Gut 23: 927-930. https://doi.org/10.1136/gut.23.11.927
    [71] Bertoletti A, Le Bert N, Qui M, et al. (2021) SARS-CoV-2-specific T cells in infection and vaccination. Cell Mol Immunol 18: 2307-2312. https://doi.org/10.1038/s41423-021-00743-3
    [72] Bertoletti A, Ferrari C, Fiaccadori F, et al. (1991) HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 88: 10445-10449. https://doi.org/10.1073/pnas.88.23.10445
    [73] Penna A, Chisari FV, Bertoletti A, et al. (1991) Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 174: 1565-1570. https://doi.org/10.1084/jem.174.6.1565
    [74] Penna A, Del Prete G, Cavalli A, et al. (1997) Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 25: 1022-1027. https://doi.org/10.1002/hep.510250438
    [75] Li J, Wang J, Kang AS, et al. (2020) Mapping the T cell response to COVID-19. Signal Transduct Target Ther 5: 112. https://doi.org/10.1038/s41392-020-00228-1
    [76] Grifoni A, Weiskopf D, Ramirez SI, et al. (2020) Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 181: 1489-1501 e1415. https://doi.org/10.1016/j.cell.2020.05.015
    [77] Ferretti AP, Kula T, Wang Y, et al. (2020) Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity 53: 1095-1107 e1093. https://doi.org/10.1016/j.immuni.2020.10.006
    [78] Zhu C, He G, Yin Q, et al. (2021) Molecular biology of the SARs-CoV-2 spike protein: A review of current knowledge. J Med Virol 93: 5729-5741. https://doi.org/10.1002/jmv.27132
    [79] Zhao J, Wang L, Schank M, et al. (2021) SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects. Virus Res 304: 198508. https://doi.org/10.1016/j.virusres.2021.198508
    [80] Szabo PA, Dogra P, Gray JI, et al. (2021) Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. Immunity 54: 797-814 e796. https://doi.org/10.1016/j.immuni.2021.03.005
    [81] Saris A, Reijnders TDY, Nossent EJ, et al. (2021) Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19. Thorax 76: 1010-1019. https://doi.org/10.1136/thoraxjnl-2020-216256
    [82] Grau-Exposito J, Sanchez-Gaona N, Massana N, et al. (2021) Peripheral and lung resident memory T cell responses against SARS-CoV-2. Nat Commun 12: 3010. https://doi.org/10.1038/s41467-021-23333-3
    [83] Grant RA, Morales-Nebreda L, Markov NS, et al. (2021) Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature 590: 635-641. https://doi.org/10.1038/s41586-020-03148-w
    [84] Urra JM, Cabrera CM, Porras L, et al. (2020) Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients. Clin Immunol 217: 108486. https://doi.org/10.1016/j.clim.2020.108486
    [85] Zimmermann P, Curtis N (2019) Factors that influence the immune response to vaccination. Clin Microbiol Rev 32: e00084-18. https://doi.org/10.1128/CMR.00084-18
    [86] Olliaro P, Torreele E, Vaillant M (2021) COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room. Lancet Microbe 2: e279-e280. https://doi.org/10.1016/S2666-5247(21)00069-0
    [87] Fiolet T, Kherabi Y, MacDonald CJ, et al. (2022) Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect 28: 202-221. https://doi.org/10.1016/j.cmi.2021.10.005
    [88] Li H, Yu J, Cao B (2021) SARS-CoV-2 vaccination for immune-comprised patients: More is required. Lancet Reg Health Eur 9: 100191. https://doi.org/10.1016/j.lanepe.2021.100191
    [89] Weinberger B (2021) Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. Immun Ageing 18: 38. https://doi.org/10.1186/s12979-021-00249-6
    [90] Shroff RT, Chalasani P, Wei R, et al. (2021) Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med 27: 2002-2011. https://doi.org/10.1038/s41591-021-01542-z
    [91] Alexander JL, Kennedy NA, Lees CW, et al. (2021) SARS-CoV-2 vaccination for patients with inflammatory bowel disease-Authors' reply. Lancet Gastroenterol Hepatol 6: 523-524. https://doi.org/10.1016/S2468-1253(21)00194-1
    [92] Moor MB, Suter-Riniker F, Horn MP, et al. (2021) Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol 3: e789-e797. https://doi.org/10.1016/S2665-9913(21)00251-4
    [93] Boyarsky BJ, Werbel WA, Avery RK, et al. (2021) Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 325: 2204-2206. https://doi.org/10.1001/jama.2021.7489
    [94] Rabinowich L, Grupper A, Baruch R, et al. (2021) Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol 75: 435-438. https://doi.org/10.1016/j.jhep.2021.04.020
    [95] Meng Z, Zhang J, Shi J, et al. (2020) Immunogenicity of influenza vaccine in elderly people: a systematic review and meta-analysis of randomized controlled trials, and its association with real-world effectiveness. Hum Vaccin Immunother 16: 2680-2689. https://doi.org/10.1080/21645515.2020.1747375
    [96] Collier DA, Ferreira I, Kotagiri P, et al. (2021) Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596: 417-422. https://doi.org/10.1038/s41586-021-03739-1
    [97] Cerqueira-Silva T, Oliveira VA, Boaventura VS, et al. (2022) Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study. Lancet Reg Health Am 6: 100154. https://doi.org/10.1016/j.lana.2021.100154
    [98] Botton J, Dray-Spira R, Baricault B, et al. (2022) Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines. Vaccine 40: 414-417. https://doi.org/10.1016/j.vaccine.2021.12.009
    [99] Ventura MT, Casciaro M, Gangemi S, et al. (2017) Immunosenescence in aging: between immune cells depletion and cytokines up-regulation. Clin Mol Allergy 15: 21. https://doi.org/10.1186/s12948-017-0077-0
    [100] Kirkwood KL (2018) Inflammaging. Immunol Invest 47: 770-773. https://doi.org/10.1080/08820139.2018.1552392
    [101] Kuderer NM, Choueiri TK, Shah DP, et al. (2020) Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 395: 1907-1918. https://doi.org/10.1016/S0140-6736(20)31187-9
    [102] Monin L, Laing AG, Munoz-Ruiz M, et al. (2021) Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 22: 765-778. https://doi.org/10.1016/S1470-2045(21)00213-8
    [103] Latif MB, Shukla S, Del Rio Estrada PM, et al. (2021) Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. Transl Res . https://doi.org/10.1016/j.trsl.2021.12.001
    [104] Mansi L, Spehner L, Daguindau E, et al. (2021) Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. Eur J Cancer 150: 1-9. https://doi.org/10.1016/j.ejca.2021.03.033
    [105] Luqmani YA, El Hashim A (2021) The COVID-19 pandemic: A health crisis managed or a panic response with disastrous future consequences?. Med Princ Pract 31: 1-10. https://doi.org/10.1159/000520258
    [106] Tarke A, Sidney J, Methot N, et al. (2021) Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals. Cell Rep Med 2: 100355. https://doi.org/10.1016/j.xcrm.2021.100355
    [107] Thanabalan A, Kiarie EG (2021) Influence of feeding Omega-3 Polyunsaturated fatty acids to broiler breeders on indices of immunocompetence, gastrointestinal, and skeletal development in broiler chickens. Front Vet Sci 8: 653152. https://doi.org/10.3389/fvets.2021.653152
    [108] Hogenkamp A, van Vlies N, Fear AL, et al. (2011) Dietary fatty acids affect the immune system in male mice sensitized to ovalbumin or vaccinated with influenza. J Nutr 141: 698-702. https://doi.org/10.3945/jn.110.135863
    [109] Yuan J, Roshdy AR, Guo Y, et al. (2014) Effect of dietary vitamin A on reproductive performance and immune response of broiler breeders. PLoS One 9: e105677. https://doi.org/10.1371/journal.pone.0105677
    [110] Quigley JD, Hill TM, Dennis TS, et al. (2021) Effects of mixed tocopherols added to milk replacer and calf starter on intake, growth, and indices of stress. J Dairy Sci 104: 9769-9783. https://doi.org/10.3168/jds.2020-19929
    [111] Nonnecke BJ, Foote MR, Miller BL, et al. (2009) Effects of chronic environmental cold on growth, health, and select metabolic and immunologic responses of preruminant calves. J Dairy Sci 92: 6134-6143. https://doi.org/10.3168/jds.2009-2517
    [112] Calder PC (2013) Feeding the immune system. Proc Nutr Soc 72: 299-309. https://doi.org/10.1017/S0029665113001286
    [113] Friedman A, Sklan D (1995) Effect of dietary fatty acids on antibody production and fatty acid composition of lymphoid organs in broiler chicks. Poult Sci 74: 1463-1469. https://doi.org/10.3382/ps.0741463
    [114] Korver DR, Klasing KC (1997) Dietary fish oil alters specific and inflammatory immune responses in chicks. J Nutr 127: 2039-2046. https://doi.org/10.1093/jn/127.10.2039
    [115] Hayek MG, Han SN, Wu D, et al. (1999) Dietary conjugated linoleic acid influences the immune response of young and old C57BL/6NCrlBR mice. J Nutr 129: 32-38. https://doi.org/10.1093/jn/129.1.32
    [116] Andresen AMS, Lutfi E, Ruyter B, et al. (2019) Interaction between dietary fatty acids and genotype on immune response in Atlantic salmon (Salmo salar) after vaccination: A transcriptome study. PLoS One 14: e0219625. https://doi.org/10.1371/journal.pone.0219625
    [117] Carman JA, Pond L, Nashold F, et al. (1992) Immunity to Trichinella spiralis infection in vitamin A-deficient mice. J Exp Med 175: 111-120. https://doi.org/10.1084/jem.175.1.111
    [118] Lee GY, Han SN (2018) The role of vitamin E in immunity. Nutrients 10: 1614. https://doi.org/10.3390/nu10111614
    [119] Penkert RR, Surman SL, Jones BG, et al. (2016) Vitamin A deficient mice exhibit increased viral antigens and enhanced cytokine/chemokine production in nasal tissues following respiratory virus infection despite the presence of FoxP3+ T cells. Int Immunol 28: 139-152. https://doi.org/10.1093/intimm/dxv064
    [120] Wang Z, Wang Y, Xu B, et al. (2017) Vitamin D improves immune function in immunosuppressant mice induced by glucocorticoid. Biomed Rep 6: 120-124. https://doi.org/10.3892/br.2016.817
    [121] Surman SL, Jones BG, Woodland DL, et al. (2017) Enhanced CD103 expression and reduced frequencies of virus-specific CD8(+) T cells among airway lymphocytes after influenza vaccination of mice deficient in vitamins A + D. Viral Immunol 30: 737-743. https://doi.org/10.1089/vim.2017.0086
    [122] Surman SL, Penkert RR, Jones BG, et al. (2016) vitamin supplementation at the time of immunization with a cold-adapted influenza virus vaccine corrects poor mucosal antibody responses in mice deficient for vitamins A and D. Clin Vaccine Immunol 23: 219-227. https://doi.org/10.1128/CVI.00739-15
    [123] Meydani SN, Meydani M, Verdon CP, et al. (1986) Vitamin E supplementation suppresses prostaglandin E1(2) synthesis and enhances the immune response of aged mice. Mech Ageing Dev 34: 191-201. https://doi.org/10.1016/0047-6374(86)90034-5
    [124] Marko MG, Ahmed T, Bunnell SC, et al. (2007) Age-associated decline in effective immune synapse formation of CD4(+) T cells is reversed by vitamin E supplementation. J Immunol 178: 1443-1449. https://doi.org/10.4049/jimmunol.178.3.1443
    [125] Marko MG, Pang HJ, Ren Z, et al. (2009) Vitamin E reverses impaired linker for activation of T cells activation in T cells from aged C57BL/6 mice. J Nutr 139: 1192-1197. https://doi.org/10.3945/jn.108.103416
    [126] Quintilio W, de Freitas FA, Rodriguez D, et al. (2016) Vitamins as influenza vaccine adjuvant components. Arch Virol 161: 2787-2795. https://doi.org/10.1007/s00705-016-2994-5
    [127] Radhakrishnan AK, Mahalingam D, Selvaduray KR, et al. (2013) Supplementation with natural forms of vitamin E augments antigen-specific TH1-type immune response to tetanus toxoid. Biomed Res Int 2013: 782067. https://doi.org/10.1155/2013/782067
    [128] Kelley DS, Taylor PC, Nelson GJ, et al. (1997) Effects of dietary arachidonic acid on human immune response. Lipids 32: 449-456. https://doi.org/10.1007/s11745-997-0059-3
    [129] Calder PC (1998) Immunoregulatory and anti-inflammatory effects of n-3 polyunsaturated fatty acids. Braz J Med Biol Res 31: 467-490. https://doi.org/10.1590/S0100-879X1998000400002
    [130] Al-Khalaifah H (2020) Modulatory effect of dietary polyunsaturated fatty acids on immunity, represented by phagocytic activity. Front Vet Sci 7: 569939. https://doi.org/10.3389/fvets.2020.569939
    [131] Dzopalic T, Bozic-Nedeljkovic B, Jurisic V (2021) The role of vitamin A and vitamin D in modulation of the immune response with a focus on innate lymphoid cells. Cent Eur J Immunol 46: 264-269. https://doi.org/10.5114/ceji.2021.103540
    [132] Schwalfenberg GK (2011) A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. Mol Nutr Food Res 55: 96-108. https://doi.org/10.1002/mnfr.201000174
    [133] Mora JR, Iwata M, von Andrian UH (2008) Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 8: 685-698. https://doi.org/10.1038/nri2378
    [134] Huang Z, Liu Y, Qi G, et al. (2018) Role of vitamin A in the immune system. J Clin Med 7: 258. https://doi.org/10.3390/jcm7090258
    [135] Motoyama KR, Curb JD, Kadowaki T, et al. (2009) Association of serum n-6 and n-3 polyunsaturated fatty acids with lipids in 3 populations of middle-aged men. Am J Clin Nutr 90: 49-55. https://doi.org/10.3945/ajcn.2008.26761
    [136] Abdelmagid SA, Clarke SE, Nielsen DE, et al. (2015) Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults. PLoS One 10: e0116195. https://doi.org/10.1371/journal.pone.0116195
    [137] Mariamenatu AH, Abdu EM (2021) Overconsumption of Omega-6 Polyunsaturated fatty acids (PUFAs) versus deficiency of Omega-3 PUFAs in modern-day diets: The disturbing factor for their “balanced antagonistic metabolic functions” in the human body. J Lipids 2021: 8848161. https://doi.org/10.1155/2021/8848161
    [138] Han X, Ding S, Lu J, et al. (2022) Global, regional, and national burdens of common micronutrient deficiencies from 1990 to 2019: A secondary trend analysis based on the Global Burden of Disease 2019 study. E Clinical Medicine 44: 101299. https://doi.org/10.1016/j.eclinm.2022.101299
    [139] Zhao T, Liu S, Zhang R, et al. (2022) Global burden of vitamin A deficiency in 204 countries and territories from 1990–2019. Nutrients 14: 950. https://doi.org/10.2139/ssrn.4005132
    [140] Palacios C, Gonzalez L (2014) Is vitamin D deficiency a major global public health problem?. J Steroid Biochem Mol Biol 144 Pt A: 138-145. https://doi.org/10.1016/j.jsbmb.2013.11.003
    [141] Sundaram ME, Talbot HK, Zhu Y, et al. (2013) Vitamin D is not associated with serologic response to influenza vaccine in adults over 50 years old. Vaccine 31: 2057-2061. https://doi.org/10.1016/j.vaccine.2013.02.028
    [142] Lee MD, Lin CH, Lei WT, et al. (2018) Does vitamin D deficiency affect the immunogenic responses to influenza vaccination? A systematic review and meta-analysis. Nutrients 10: 409. https://doi.org/10.3390/nu10040409
    [143] (2000) Institute of Medicine (US) Panel on Dietary Antioxidants and Related CompoundsDietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington (DC): National Academies Press.
    [144] Peter S, Friedel A, Roos FF, et al. (2015) A systematic review of global alpha-tocopherol status as assessed by nutritional intakelevels and blood serum concentrations. Int J Vitam Nutr Res 85: 261-281. https://doi.org/10.1024/0300-9831/a000281
    [145] Ford ES, Schleicher RL, Mokdad AH, et al. (2006) Distribution of serum concentrations of alpha-tocopherol and gamma-tocopherol in the US population. Am J Clin Nutr 84: 375-383. https://doi.org/10.1093/ajcn/84.1.375
    [146] Malik A, Eggersdorfer M, Trilok-Kumar G (2021) Vitamin E status in healthy population in Asia: A review of current literature. Int J Vitam Nutr Res 91: 356-369. https://doi.org/10.1024/0300-9831/a000590
    [147] Meydani SN, Han SN, Wu D (2005) Vitamin E and immune response in the aged: molecular mechanisms and clinical implications. Immunol Rev 205: 269-284. https://doi.org/10.1111/j.0105-2896.2005.00274.x
    [148] Murphy S, West KP, Greenough WB, et al. (1992) Impact of vitamin A supplementation on the incidence of infection in elderly nursing-home residents: a randomized controlled trial. Age Ageing 21: 435-439. https://doi.org/10.1093/ageing/21.6.435
    [149] Buzina-Suboticanec K, Buzina R, Stavljenic A, et al. (1998) Ageing, nutritional status and immune response. Int J Vitam Nutr Res 68: 133-141.
    [150] Wu D, Meydani SN (2008) Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention. J Leukoc Biol 84: 900-914. https://doi.org/10.1189/jlb.0108023
    [151] Wu D, Meydani SN (2014) Age-associated changes in immune function: impact of vitamin E intervention and the underlying mechanisms. Endocr Metab Immune Disord Drug Targets 14: 283-289. https://doi.org/10.2174/1871530314666140922143950
    [152] Camargo CQ, Brunetta HS, Nunes EA (2018) Effects of cotreatment with omega-3 polyunsaturated fatty acids and anticancer agents on oxidative stress parameters: a systematic review of in vitro, animal, and human studies. Nutr Rev 76: 765-777. https://doi.org/10.1093/nutrit/nuy029
    [153] Story MJ (2021) Zinc, omega-3 polyunsaturated fatty acids and vitamin D: An essential combination for prevention and treatment of cancers. Biochimie 181: 100-122. https://doi.org/10.1016/j.biochi.2020.11.019
    [154] Yuen RC, Tsao SY (2021) Embracing cancer immunotherapy with vital micronutrients. World J Clin Oncol 12: 712-724. https://doi.org/10.5306/wjco.v12.i9.712
    [155] Chisari FV, Ferrari C (1995) Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13: 29-60. https://doi.org/10.1146/annurev.iy.13.040195.000333
    [156] Matchett WE, Joag V, Stolley JM, et al. (2021) Cutting Edge: Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. J Immunol 207: 376-379. https://doi.org/10.4049/jimmunol.2100421
    [157] Fiorino S, Gallo C, Zippi M, et al. (2020) Cytokine storm in aged people with CoV-2: possible role of vitamins as therapy or preventive strategy. Aging Clin Exp Res 32: 2115-2131. https://doi.org/10.1007/s40520-020-01669-y
    [158] Fiorino S, Zippi M, Gallo C, et al. (2021) The rationale for a multi-step therapeutic approach based on antivirals, drugs and nutrients with immunomodulatory activity in patients with coronavirus-SARS2-induced disease of different severities. Br J Nutr 125: 275-293. https://doi.org/10.1017/S0007114520002913
    [159] Husson MO, Ley D, Portal C, et al. (2016) Modulation of host defence against bacterial and viral infections by omega-3 polyunsaturated fatty acids. J Infect 73: 523-535. https://doi.org/10.1016/j.jinf.2016.10.001
    [160] Chiang N, Serhan CN (2020) Specialized pro-resolving mediator network: an update on production and actions. Essays Biochem 64: 443-462. https://doi.org/10.1042/EBC20200018
    [161] Panigrahy D, Gilligan MM, Huang S, et al. (2020) Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?. Cancer Metastasis Rev 39: 337-340. https://doi.org/10.1007/s10555-020-09889-4
    [162] Gallo CG, Fiorino S, Posabella G, et al. (2022) The function of specialized pro-resolving endogenous lipid mediators, vitamins, and other micronutrients in the control of the inflammatory processes: Possible role in patients with SARS-CoV-2 related infection. Prostaglandins Other Lipid Mediat 159: 106619. https://doi.org/10.1016/j.prostaglandins.2022.106619
    [163] Sedighiyan M, Abdollahi H, Karimi E, et al. (2021) Omega-3 polyunsaturated fatty acids supplementation improve clinical symptoms in patients with Covid-19: A randomised clinical trial. Int J Clin Pract 75: e14854. https://doi.org/10.1111/ijcp.14854
    [164] Rogero MM, Leao MC, Santana TM, et al. (2020) Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19. Free Radic Biol Med 156: 190-199. https://doi.org/10.1016/j.freeradbiomed.2020.07.005
    [165] Ross AC, Chen Q, Ma Y (2011) Vitamin A and retinoic acid in the regulation of B-cell development and antibody production. Vitam Horm 86: 103-126. https://doi.org/10.1016/B978-0-12-386960-9.00005-8
    [166] Azzi L, Dalla Gasperina D, Veronesi G, et al. (2022) Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. E Bio Medicine 75: 103788. https://doi.org/10.1016/j.ebiom.2021.103788
    [167] Hughes DA, Norton R (2009) Vitamin D and respiratory health. Clin Exp Immunol 158: 20-25. https://doi.org/10.1111/j.1365-2249.2009.04001.x
    [168] Parekh D, Thickett DR, Turner AM (2013) Vitamin D deficiency and acute lung injury. Inflamm Allergy Drug Targets 12: 253-261. https://doi.org/10.2174/18715281113129990049
    [169] Remmelts HH, van de Garde EM, Meijvis SC, et al. (2012) Addition of vitamin D status to prognostic scores improves the prediction of outcome in community-acquired pneumonia. Clin Infect Dis 55: 1488-1494. https://doi.org/10.1093/cid/cis751
    [170] Dancer RC, Parekh D, Lax S, et al. (2015) Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax 70: 617-624. https://doi.org/10.1136/thoraxjnl-2014-206680
    [171] Borsche L, Glauner B, von Mendel J (2021) COVID-19 mortality risk correlates inversely with vitamin D3 status, and a mortality rate close to zero could theoretically be achieved at 50 ng/mL 25(OH)D3: results of a systematic review and meta-analysis. Nutrients 13: 3596. https://doi.org/10.3390/nu13103596
    [172] Ebrahimzadeh A, Mohseni S, Narimani B, et al. (2021) Association between vitamin D status and risk of covid-19 in-hospital mortality: A systematic review and meta-analysis of observational studies. Crit Rev Food Sci Nutr : 1-11. https://doi.org/10.1080/10408398.2021.2012419
    [173] Dissanayake HA, de Silva NL, Sumanatilleke M, et al. (2021) Prognostic and therapeutic role of vitamin D in COVID-19: systematic review and meta-analysis. J Clin Endocrinol Metab 107: 1484-1502. https://doi.org/10.1210/clinem/dgab892
    [174] Tentolouris N, Samakidou G, Eleftheriadou I, et al. (2021) The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients. A systematic review, meta-analysis and meta-regression. Diabetes Metab Res Rev : e3517. https://doi.org/10.1002/dmrr.3517
    [175] Hu Y, Kung J, Cave A, et al. (2022) Effects of Vitamin D Serum Level on Morbidity and Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis. J Pharm Pharm Sci 25: 84-92. https://doi.org/10.18433/jpps32590
    [176] Chen J, Mei K, Xie L, et al. (2021) Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs. Nutr J 20: 89. https://doi.org/10.1186/s12937-021-00744-y
    [177] Pallast EG, Schouten EG, de Waart FG, et al. (1999) Effect of 50- and 100-mg vitamin E supplements on cellular immune function in noninstitutionalized elderly persons. Am J Clin Nutr 69: 1273-1281. https://doi.org/10.1093/ajcn/69.6.1273
    [178] Andreone P, Fiorino S, Cursaro C, et al. (2001) Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. Antiviral Res 49: 75-81. https://doi.org/10.1016/S0166-3542(00)00141-8
    [179] Fiorino S, Loggi E, Verucchi G, et al. (2017) Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. Liver Int 37: 54-61. https://doi.org/10.1111/liv.13192
    [180] Gerner P, Posselt HG, Krahl A, et al. (2008) Vitamin E treatment for children with chronic hepatitis B: a randomized placebo controlled trial. World J Gastroenterol 14: 7208-7213. https://doi.org/10.3748/wjg.14.7208
    [181] Dikici B, Dagli A, Ucmak H, et al. (2007) Efficacy of vitamin E in children with immunotolerant-phase chronic hepatitis B infection. Pediatr Int 49: 603-607. https://doi.org/10.1111/j.1442-200X.2007.02419.x
    [182] Fiorino S, Bacchi-Reggiani ML, Leandri P, et al. (2017) Vitamin E for the treatment of children with hepatitis B e antigen-positive chronic hepatitis: A systematic review and meta-analysis. World J Hepatol 9: 333-342. https://doi.org/10.4254/wjh.v9.i6.333
  • This article has been cited by:

    1. Michael Schuster, Elisa Strauch, Martin Gugat, Jens Lang, Probabilistic constrained optimization on flow networks, 2022, 23, 1389-4420, 1, 10.1007/s11081-021-09619-x
    2. Martin Gugat, Michael Herty, 2022, 23, 9780323850599, 59, 10.1016/bs.hna.2021.12.002
    3. María Concepción López-Díaz, Miguel López-Díaz, On the Axial Symmetry of 2D Star-Shaped Sets, 2025, 67, 0924-9907, 1, 10.1007/s10851-024-01222-w
    4. Martin Gugat, Michael Schuster, Jan Sokołowski, The location problem for compressor stations in pipeline networks, 2024, 12, 2325-3444, 507, 10.2140/memocs.2024.12.507
    5. Andrea Corli, Massimiliano D. Rosini, Ulrich Razafison, 2024, Mathematical Modeling of Chattering and the Optimal Design of a Valve*, 979-8-3503-1633-9, 76, 10.1109/CDC56724.2024.10886245
    6. Andrea Corli, Ulrich Razafison, Massimiliano D. Rosini, Coherence of Coupling Conditions for the Isothermal Euler System, 2025, 0170-4214, 10.1002/mma.10847
  • Reader Comments
  • © 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(2235) PDF downloads(137) Cited by(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog